195 related articles for article (PubMed ID: 25340858)
1. Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer.
Lin L; Piao J; Ma Y; Jin T; Quan C; Kong J; Li Y; Lin Z
PLoS One; 2014; 9(10):e111260. PubMed ID: 25340858
[TBL] [Abstract][Full Text] [Related]
2. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
3. DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.
Feng T; Liu Y; Li C; Li Z; Cai H
Tumour Biol; 2017 Jul; 39(7):1010428317716248. PubMed ID: 28670979
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.
Wise-Draper TM; Allen HV; Jones EE; Habash KB; Matsuo H; Wells SI
Mol Cell Biol; 2006 Oct; 26(20):7506-19. PubMed ID: 16894028
[TBL] [Abstract][Full Text] [Related]
5. The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK.
Qian Z; Yang J; Liu H; Yin Y; Hou L; Hu H
Folia Histochem Cytobiol; 2019; 57(2):64-73. PubMed ID: 31246264
[TBL] [Abstract][Full Text] [Related]
6. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
7. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
8. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
9. KIF15 upregulation promotes leiomyosarcoma cell growth via promoting USP15-mediated DEK deubiquitylation.
Ge W; Chen Y; Guo Y; Zhao D; Mu L; Zhang K; Zhuo W
Biochem Biophys Res Commun; 2021 Sep; 570():117-124. PubMed ID: 34280614
[TBL] [Abstract][Full Text] [Related]
10. Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3.
You S; Guan Y; Li W
Mol Med Rep; 2018 Jan; 17(1):1065-1070. PubMed ID: 29115492
[TBL] [Abstract][Full Text] [Related]
11. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
12. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
[TBL] [Abstract][Full Text] [Related]
13. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
14. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
[TBL] [Abstract][Full Text] [Related]
15. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
16. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
17. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
[TBL] [Abstract][Full Text] [Related]
18. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
[TBL] [Abstract][Full Text] [Related]
19. LCMR1 interacts with DEK to suppress apoptosis in lung cancer cells.
Xu Y; Liang Z; Li C; Yang Z; Chen L
Mol Med Rep; 2017 Oct; 16(4):4159-4164. PubMed ID: 28765911
[TBL] [Abstract][Full Text] [Related]
20. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
